Sign In
Buy ILMN
$205.10
+0.0100 (+0.0049%)
At Close: Jul 31, 2026
Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?
11:31am, Thursday, 09'th Jul 2026
ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat
11:07am, Thursday, 09'th Jul 2026
Illumina commands 90%+ market share in genomics sequencing, powering a $30B+ TAM growing at double digits with a robust razor-and-blades model. Post-GRAIL, management's renewed focus on core sequencin
Here's Why Illumina (ILMN) is a Strong Momentum Stock
10:51am, Thursday, 09'th Jul 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
09:05am, Thursday, 09'th Jul 2026
New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the ap
Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs
03:05pm, Wednesday, 08'th Jul 2026
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 08'th Jul 2026
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 08'th Jul 2026
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Continue to Hold ILMN Stock in Your Portfolio?
09:55am, Friday, 03'rd Jul 2026
Illumina builds on strong NovaSeq X demand and clinical sequencing momentum, but China weakness and cost pressures keep challenges in focus.
AZN vs. ILMN: Which Stock Should Value Investors Buy Now?
12:40pm, Wednesday, 01'st Jul 2026
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value invest
Here's Why Illumina (ILMN) is a Strong Growth Stock
10:46am, Monday, 29'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
04:07am, Monday, 29'th Jun 2026
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
09:05am, Tuesday, 23'rd Jun 2026
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 17'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
10:47am, Thursday, 11'th Jun 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
